表紙
市場調査レポート

非アルコール性脂肪肝疾患(NAFLD): パイプライン分析

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 251566
出版日 ページ情報 英文 144 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
非アルコール性脂肪肝疾患(NAFLD): パイプライン分析 Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2016
出版日: 2016年07月20日 ページ情報: 英文 144 Pages
概要

非アルコール性脂肪肝疾患は、慢性肝疾患の最も一般的な原因の1つです。この疾患は、よく見られる病気で、ほとんどの人は症侯や合併症が見られませんが、人によっては蓄積された脂肪のせいで肝臓に炎症や傷を引き起こすことがあります。 最も顕著な症状としては、倦怠感、疲労感、腹部の右上四分の一か全体に広がる不快感があります。

当レポートでは、非アルコール性脂肪肝疾患(NAFLD)の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

非アルコール性脂肪肝疾患(NAFLD) 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Arisaph Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Betagenon AB
  • Can-Fite BioPharma Ltd.
  • Conatus Pharmaceuticals Inc.
  • Corcept Therapeutics Incorporated
  • Daewoong Pharmaceutical Co., Ltd.
  • Dimerix Bioscience Pty Ltd
  • Dr. Falk Pharma GmbH
  • DURECT Corporation
  • Galmed Pharmaceuticals Ltd.
  • Gilead Sciences, Inc.
  • Huons Co., Ltd.
  • キョーリン製薬
  • Novartis AG
  • Sancilio & Company, Inc.
  • TaiwanJ Pharmaceuticals Co., Ltd.
  • TCM Biotech International Corp
  • Tobira Therapeutics, Inc.
  • Verva Pharmaceuticals Limited
  • Zafgen Inc.
  • Zydus Cadila Healthcare Limited

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (ロイシン + 塩酸メトホルミン + クエン酸シルデナフィル)
  • (ロイシン + PDE5 阻害剤)
  • Aramchol
  • ARI-3037MO
  • C-10
  • cenicriviroc mesylate
  • CF-102
  • CORT-118335
  • DMX-300
  • 消化器疾患・代謝障害治療用 ABHD6阻害薬
  • DUR-928
  • DWP-10292
  • emricasan
  • FLB-12
  • GS-9674
  • HU-002
  • KDT-501
  • MAT-8800
  • methazolamide
  • MN-002
  • 塩酸ナルトレキソン
  • norursodeoxycholic acid
  • O-304
  • oltipraz
  • pradigastat sodium
  • Px-103
  • saroglitazar
  • SC-410
  • 非アルコール性脂肪性肝炎・非アルコール性脂肪肝疾患治療薬
  • 脂肪肝疾患治療用AMPK活性薬
  • 代謝障害治療用 NaCT阻害剤
  • TCM-606F
  • VVP-100-X
  • ZGN-839

最近のパイプライン動向

休止中のプロジェクト

)■開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8300IDB

Summary

Global Markets Direct's, 'Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2016', provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD)
  • The report reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics and enlists all their major and minor projects
  • The report assesses Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Non Alcoholic Fatty Liver Disease (NAFLD) Overview
  • Therapeutics Development
    • Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) - Overview
    • Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics under Development by Companies
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics under Investigation by Universities/Institutes
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Products under Development by Companies
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Products under Investigation by Universities/Institutes
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development
    • Arisaph Pharmaceuticals, Inc.
    • AstraZeneca Plc
    • Betagenon AB
    • Can-Fite BioPharma Ltd.
    • Cerenis Therapeutics Holding SA
    • Conatus Pharmaceuticals Inc.
    • Corcept Therapeutics Incorporated
    • Daewoong Pharmaceutical Co., Ltd.
    • Dimerix Bioscience Pty Ltd
    • Dr. Falk Pharma GmbH
    • DURECT Corporation
    • Eternygen GmbH
    • Galmed Pharmaceuticals Ltd.
    • Huons Co., Ltd.
    • Kyorin Pharmaceutical Co., Ltd.
    • Matinas BioPharma Holdings, Inc.
    • Novartis AG
    • NovaTarg Therapeutics, Inc
    • Osel, Inc.
    • Sancilio & Company, Inc.
    • TaiwanJ Pharmaceuticals Co., Ltd.
    • TCM Biotech International Corp
    • Tobira Therapeutics, Inc.
    • Zafgen Inc.
    • Zydus Cadila Healthcare Limited
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (leucine + PDE5 Inhibitor) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AC-261066 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Aramchol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARI-3037MO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-4076 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CBM-588 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cenicriviroc mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CER-209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CF-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CORT-118335 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dapagliflozin propanediol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DMX-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DUR-928 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWP-10292 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emricasan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FLB-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HU-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KDT-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAT-8800 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MN-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naltrexone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • norursodeoxycholic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • O-304 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oltipraz - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pradigastat sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RT-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RT-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • saroglitazar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SC-410 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NaCT for Metabolic Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TCM-606F - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZGN-839 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 10, 2016: NuSirt Biopharma Presents Data on NS-0200 at American Diabetes Association's 76th Annual Scientific Sessions
      • Jun 07, 2016: Galmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China
      • Jun 01, 2016: Galmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial
      • May 24, 2016: Two presentations highlighting Zydus drug, Lipaglyn will be featured at the AACE Annual meeting
      • Mar 30, 2016: Aramchol Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease
      • Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study
      • Jan 11, 2016: Can-Fite Announces Update on CF102
      • Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-928
      • Dec 10, 2015: NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment
      • Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease
      • Oct 08, 2015: NuSirt Biopharma Plans Clinical Trial in Non-Alcoholic Fatty Liver Disease
      • May 18, 2015: DURECT Announces Positive Results from DUR-928 Multi-Dose Phase 1 Study
      • Apr 23, 2015: Conatus Clinical Results at EASL Meeting Support Emricasan Registration Pathway in NASH
      • Apr 08, 2015: Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting
      • Mar 30, 2015: DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2016
  • Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by AstraZeneca Plc, H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Betagenon AB, H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Can-Fite BioPharma Ltd., H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Cerenis Therapeutics Holding SA, H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Conatus Pharmaceuticals Inc., H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Corcept Therapeutics Incorporated, H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dr. Falk Pharma GmbH, H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by DURECT Corporation, H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Eternygen GmbH, H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Galmed Pharmaceuticals Ltd., H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Huons Co., Ltd., H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Novartis AG, H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by NovaTarg Therapeutics, Inc, H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Osel, Inc., H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Sancilio & Company, Inc., H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TCM Biotech International Corp, H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Tobira Therapeutics, Inc., H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zafgen Inc., H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects (Contd..1), H2 2016
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2016
  • Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top